 CONSHOHOCKEN, Pa., June 25, 2021 GLOBE NEWSWIRE -- Madrigal Pharmaceuticals, Inc. NASDAQ:MDGL, today announced the presentation of positive clinical data from the open-label portion of its ongoing Phase 3 MAESTRO-NAFLD-1 study of resmetirom at the European Association for the Study of the Liver Annual Meeting, The International Liver CongressTM 2021, being held virtually, June 23-26, 2021. The data continue to position resmetirom as a promising treatment option for nonalcoholic steatohepatitis NASH patients. 